New drug cocktail shows promise for advanced kidney cancer in early trial
NCT ID NCT05030506
First seen Jan 04, 2026 · Last updated Apr 24, 2026 · Updated 12 times
Summary
This early-phase study tests a new drug called belzutifan, alone or combined with lenvatinib and pembrolizumab, in about 45 Chinese adults with advanced kidney cancer that cannot be removed by surgery. The main goals are to check safety and how the body processes the drugs. This is not a cure, but aims to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer hospital-Digestive Oncology ( Site 0001)
Beijing, Beijing Municipality, 100142, China
-
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Urology ( S
Nanjing, Jiangsu, 210000, China
-
SUN YAT-SEN UNIVERSITY CANCER CENTRE-Urology Surgery Department ( Site 0005)
Guangzhou, Guangdong, 510060, China
-
The Second Affiliated hospital of Zhejiang University school of medicine-Urology ( Site 0007)
Hangzhou, Zhejiang, 310052, China
-
Tianjin Medical University Cancer Institute and Hospital ( Site 0003)
Tianjin, Tianjin Municipality, 300060, China
Conditions
Explore the condition pages connected to this study.